Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | CD40 | P25942 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958851 | 1.00 | SLC15A2 (0.50) | SLC15A2TERTCD40MMP2C5AR1 | |
| SCHEMBL31453807 | 0.96 | SLC15A2 (0.50) | SLC15A2TERTCD40C5AR1ERAP2 | |
| SCHEMBL31514351 | 0.94 | SLC15A2 (0.48) | SLC15A2TERTCD40C5AR1ERAP2 | |
| SCHEMBL8832514 | 0.94 | TERT (0.44) | SLC15A2TERTCD40MMP2ERAP2 | |
| SCHEMBL2823387 | 0.94 | TERT (0.44) | SLC15A2TERTCD40MMP2ERAP2 | |
| SCHEMBL30670352 | 0.94 | SLC15A2 (0.48) | SLC15A2TERTCD40C5AR1ERAP2 | |
| SCHEMBL8832652 | 0.93 | TERT (0.44) | SLC15A2TERTCD40MMP2ERAP2 | |
| SCHEMBL31282809 | 0.93 | TERT (0.42) | SLC15A2TERTCD40MMP2 | |
| SCHEMBL9748489 | 0.92 | SLC15A2 (0.46) | SLC15A2TERTCD40MMP2ERAP2 | |
| SCHEMBL8427583 | 0.92 | SLC15A2 (0.46) | SLC15A2TERTCD40MMP2ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445431-B2 | Peptides having separate domains; AIDS, cardiovascular disease, hepatitis. diabetes, cancer; side effect reduction | THE OHIO STATE UNIVERSITY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20080188422-A1 | Ligands Having Metal Binding Ability and Targeting Properties | THE OHIO STATE UNIVERSITY RESEARCH OFFICE OF TECHNOLOGY LICENSING & COMMERCIALIZATION (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2005117997-A1 | LIGANDS HAVING METAL BINDING ABILITY AND TARGETING PROPERTIES | THE OHIO STATE UNIVERSITY (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188422-A1 | Ligands Having Metal Binding Ability and Targeting Properties | CNBP, GAA, SPR | SLC15A2 1649/4885TERT 4068/4885CD40 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.